Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Neratinib Efficacy in Patients With EGFR Exon 18-Mutant Non-Small-Cell Lung Cancer: Findings From the SUMMIT Basket Trial.
Clin Lung Cancer
December 2024
Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Medicine, Chicago, IL.
Background: Activating mutations in the epidermal growth factor receptor (EGFR) gene occur in 7% to 23% of patients with non-small-cell lung cancer (NSCLC). A small proportion of these (3-5%) are exon 18 mutations. Neratinib, an irreversible pan-HER tyrosine kinase inhibitor (TKI), had activity in the phase II SUMMIT basket study.
View Article and Find Full Text PDFBacterial enteritis caused by Salmonella Kedougou after returning from Thailand: A case report.
J Infect Chemother
January 2025
Department of Infectious Diseases, Graduate School of Medical Sciences, Nagoya City University, Aichi, Japan; Department of Clinical Infectious Diseases, Graduate School of Medical Sciences, Nagoya City University, Aichi, Japan; Department of Infectious Diseases, Nagoya City University East Medical Center, Aichi, Japan. Electronic address:
Non-typhoid Salmonella (NTS) includes many serotypes that differ in host, geographic distribution, and virulence. We report the case of a 64-year-old man who developed enteritis caused by Salmonella Kedougou without bacteremia after returning from Thailand. The patient stayed in Chiang Mai, Thailand, for 10 days to play golf and was hospitalized with fever, chills, watery diarrhea, and vomiting on the day the patient returned to Japan.
View Article and Find Full Text PDFSafety and efficacy of trifluridine/tipiracil +/- bevacizumab plus XB2001 (anti-IL-1α antibody): a single-center phase 1 trial.
Signal Transduct Target Ther
January 2025
Centre de Recherche INSERM Center for Translational and Molecular Medicine, 21000, Dijon, France.
In the tumour microenvironment, IL-1α promotes neoangiogenesis, matrix remodelling, tumour proliferation, chemoresistance, and metastases. Highly expressed in human colorectal cancers, IL-1α is associated with poor prognosis. XB2001, a fully human monoclonal antibody neutralizing IL-1α, was evaluated for safety and preliminary efficacy with trifluridine/tipiracil (FTD/TPI) and bevacizumab in metastatic colorectal cancer patients previously treated with oxaliplatin- and irinotecan-based chemotherapies.
View Article and Find Full Text PDFContinued Treatment with Nintedanib in Patients with Progressive Pulmonary Fibrosis: Data from INBUILD-ON.
Lung
January 2025
National Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, Claude Bernard University Lyon 1, UMR 754, ERN-LUNG, Lyon, France.
Purpose: In the INBUILD trial in patients with progressive pulmonary fibrosis (PPF), nintedanib slowed the decline in forced vital capacity (FVC) versus placebo, with a safety profile characterised mainly by gastrointestinal events. INBUILD-ON, the open-label extension of INBUILD, assessed the safety of nintedanib during longer-term treatment. Data on FVC were collected.
View Article and Find Full Text PDFDevelopment and Evaluation of a Remote Monitoring Regional Adjuvant Abemaciclib Service for Patients With High-Risk Early Breast Cancer.
Clin Breast Cancer
December 2024
Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK; Division of Cancer Sciences, The University of Manchester, Manchester, UK. Electronic address:
Introduction: Adjuvant abemaciclib was recently approved in high-risk early breast cancer, leading to an increase in oncology resource utilisation. We thus developed a regional, remote monitoring clinical service. The set-up, delivery processes and outcomes from the first 6 months' consecutive patients are presented.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!